Experimental studies of the JAK1/JAK2 inhibitor ruxolitinib in the LEW.1WR1 rat model demonstrate that initiating administration prior to the onset of insulitis and maintaining treatment throughout the disease progression completely prevents diabetes development (40). This evidence concerns the gene JAK1 and diabetes mellitus.